JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.
JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.